A Phase 2a, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of AL-3778 in Combination With Peginterferon Alpha-2a in Treatment Naïve Chronic Hepatitis B Subjects Who Are HBeAg-positive
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2017
At a glance
- Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Alios BioPharma
- 13 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Aug 2017 Planned End Date changed from 30 Dec 2018 to 15 Feb 2019.
- 15 Aug 2017 Planned primary completion date changed from 30 Dec 2018 to 15 Feb 2019.